Erika Hamilton, Chief Development Officer, Late Phase and Director of the Breast Cancer Research Program, shared on X:
“PANKU-Breast01.
Phase III results for Izalontamab Brengitecan (bispecific EGFR/HER3 ADC) vs TPC chemotherphy, in previously treated HR +/HER- MBC.
- mPFS: 4.0 vs. 8.1 mo, HR 0.41.
- ORR: 20% vs 40%.
- DoR: 4.2 vs. 6.9 mo.
- ILD: Only 1.1% & all grade 1/2.”
You can also read:
